Preeti Narayan, MD

Breast Oncologist at FDA, @FDAOncology
Opinions are my own.
Canadian/American hybrid 🇨🇦🇺🇸

[FDA Oncology @FDAOncology]

#FDA approves a treatment for unresectable or metastatic HER2-positive breast cancer. https://t.co/S9k6p0eH9T

[Dr. Kelly Shanahan @stage4kelly]

Unfortunately, other obligations kept me and @JaniceTNBCmets from attending our favorite @abreastcancer session with the FDA, but nothing could keep us from at least saying hi to some of our favorite @FDAOncology people! @tmprowell #SABCS24

[FDA Oncology @FDAOncology]

FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.
https://t.co/ioGzqmxTU3

#OCENewsBurst

[FDA Oncology @FDAOncology]

What are pragmatic clinical trials? Clinical trials that streamline data collection and design by collecting only necessary information to answer the research question. A thread 🧵 1/5

#ProjectPragmatica #OCEProject5in5 #PragmaticTrials

[Preeti Narayan, MD @pre_ryan]

@NBCCStopBC Thank you for having us, was great to be part of the panel

[Preeti Narayan, MD @pre_ryan]

Mentioned this OCE initiative at @NBCCStopBC Advocate summit today at the outcomes that matter panel discussion, please post any ideas for pragmatic designs! @FDAOncology @drjennifergao @DrKNorsworthy @StevenClarkCunn @DrDonnaRivera

[FDA Oncology @FDAOncology]

What is FDA Oncology's Project 5 in 5?
⏩ OCE Director Dr. Richard Pazdur explains how 𝘆𝗼𝘂 can take part in crowdsourcing to ultimately select 5 clinically relevant questions to be answered in pragmatic clinical trials.
https://t.co/OIVGCFUGf0
#OCEProject5in5

[Julia Maués @itsnot_pink]

“Dose is the foundation of drug development. Having the wrong dose is like building a house on quicksand.”

@realrickpazdur, quoted by @pre_ryan at @NBCCStopBC’s #NBCCSummit.

[Preeti Narayan, MD @pre_ryan]

@DrMMurphy @UFMedicine @UF Congrats!!! So well deserved!

[National Breast Cancer Coalition @NBCCStopBC]

Today’s #NBCCSummit panel includes @theNCI’s Larissa Korde, @pre_ryan, NBCC team leader Nicole Seagriff, and @QueensGlobalOnc’s Brooke Wilson about why oncology research should be designed to answer questions about outcomes and questions that matter for patients.

[FDA Oncology @FDAOncology]

🎇 Today, Sunday, May 5 - #CincodeMayo - We officially launch Project 5 in 5: Crowdsourcing 5 clinically relevant questions for 5 pragmatic clinical trials!

💡 What's your clinical trial idea? Sign up and submit ideas here ➡️ https://t.co/OIVGCFUGf0

#OCEProject5in5

[Harpreet Singh, MD @harpreet_md]

✨Perfect day spending time with colleagues and friends ✨@FDAOncology

[FDA Oncology @FDAOncology]

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. https://t.co/PrklmlcNRg

#OCENewsBurst

[Preeti Narayan, MD @pre_ryan]

@DrSGraff @FDAOncology @SABCSSanAntonio Really appreciated the opportunity to have this session at #SABCS23

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

I want to say I appreciate @FDAOncology coming out from behind the curtain and discussing with patients and clinicians their thoughts & rationale around recent approvals. Great session, @SABCSSanAntonio 👏🏻

[FDA Oncology @FDAOncology]

The latest episode of #OCEProjectLivinLabel - fam-Trastuzumab Deruxtecan-nxki: The Backstory – is now available!

Watch the episode and read the labeling to receive free CME credit offered by @AACR.
Click here 🔽 https://t.co/Fa7jZkbMfS

@pre_ryan #OCEProjectSocrates

[Oncology Brothers @OncBrothers]

#SABCS23 Day 1 Highlights #CommunityOnc:

@FDAOncology Review on recent approvals

1. #CAPItello291

2. #EMERALD

3. #TDxD

4. Tumor Agnostic landscape

5. Post CDK4/6i HR+

@SABCSSanAntonio @VivekSubbiah @VKaklamani @JaniceTNBCmets #bcsm @DrSGraff @oreganruth

1/6

[Elisa Agostinetto @ElisaAgostinett]

Great start at #SABCS23 with the session on New approval in metastatic #breastcancer
🔸Elacestrant
🔸T-DXd
🔸Capivasertib
Happening now at Hemisfair Ballroom 1-2
@SABCSSanAntonio
@OncoAlert

[FDA Oncology @FDAOncology]

FDA approved capivasertib with fulvestrant for HR+ HER2-neg locally advanced/metastatic breast cancer with PIK3CA/AKT1/PTEN alterations following progression on endocrine-based regimen or recurrence on completing adjuvant therapy
https://t.co/jLqjsSLT7K
Click to #OCENewsBurst ⬆️

[FDA Oncology @FDAOncology]

Today FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent dMMR or MSI-H endometrial cancer.
https://t.co/7WefziwXrN

[Preeti Narayan, MD @pre_ryan]

Important article for the oncology community on drug shortages and FDA's role, root causes for these shortages, and strategies to address -link is open access @OncoAlert

[FDA Oncology @FDAOncology]

Read an interview with OCE Director Richard Pazdur about causes of oncology drug shortages and what the FDA can and can't do to fix it, via @TheCancerLetter open access article.